Adamantylmethylamine derivative and use thereof as pharmaceutical

A compound represented by Formula (I):

• wherein Q1, Q2, R1, and R4 are each independently selected from a hydrogen atom, a halogen atom, C1-6 alkyl optionally substituted with one or more halogen atoms, amino, C6-10 aryl optionally substituted with one or more substituents selected from X1, carboxy, —OR7, and —SR8;
• R2 represents a hydrogen atom, phenylsulfonyl optionally substituted with one or more substituents selected from X1, (C1-6 alkyl)sulfonyl optionally substituted with one or more halogen atoms, or —COYR6;
• Y represents a direct bond, O, or NR9;
• R3 represents C3-8 cycloalkyl optionally substituted with one or more substituents selected from X1, C6-10 aryl optionally substituted with one or more substituents selected from X1, phenylaminocarboyl optionally substituted with one or more substituents selected from X1, 5- to 10-membered monocyclic or bicyclic heteroaryl optionally substituted with one or more substituents selected from X1, 5- to 10-membered monocyclic or bicyclic non-aromatic heterocyclyl optionally substituted with one or more substituents selected from X1, or -Q3-R13;
• Q3 represents C1-3 alkylene, or C2-3 alkenylene;
• R13 represents C6-10 aryl optionally substituted with one or more substituents selected from X1;
• R5 represents a hydrogen atom, or C1-6 alkyl optionally substituted with one or more halogen atoms;
• R6 represents C1-6 alkyl, C6-10 aryl optionally substituted with one or more substituents selected from X1, or 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X1, wherein the alkyl is optionally substituted with one or more halogen atoms, and/or is optionally substituted with one substituent selected from X2;
• R7 represents a hydrogen atom, C1-6 alkyl optionally substituted with one or more halogen atoms, C1-6 alkoxyC1-6 alkyl, (C1-6 alkyl)carbonyl optionally substituted with one or more halogen atoms, or C6-10 aryl optionally substituted with one or more substituents selected from X1;
• R8 represents a hydrogen atom, C1-6 alkyl optionally substituted with one or more halogen atoms, or C6-10 aryl optionally substituted with one or more substituents selected from X1;
• R9 represents a hydrogen atom, or C1-6 alkyl optionally substituted with one or more halogen atoms;
• each X1 is independently selected from C1-6 alkyl, a halogen atom, C1-6 alkoxy, hydroxy, nitro, and cyano;
• X2 is selected from C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, and —NR11R12;
• R11 represents a hydrogen atom, C1-6 alkyl, (C1-6 alkoxy)carbonyl, or [(C6-10 aryl)C1-3 alkoxy]carbonyl whose aryl moiety is optionally substituted with one or more substituents selected from X1, wherein the alkyl or alkoxy moiety is optionally substituted with one or more halogen atoms;
• R12 represents a hydrogen atom, or C1-6 alkyl optionally substituted with one or more halogen atoms;
• wherein the methylene present in the adamantyl group is optionally substituted with one or more groups independently selected from C1-6 alkyl, C1-6 alkoxy, and hydroxy, wherein the alkyl or alkoxy is optionally substituted with one or more halogen atoms,
• wherein the methylene moiety of the monocyclic or bicyclic non-aromatic heterocyclyl is optionally substituted with oxo,
• an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof.